J.P. Morgan Notebook Day 4: Kite, Cellectis and MannKind

Kite Pharma Inc. presented the latest data from a trial of KTE-C19 in non-Hodgkin lymphoma as further evidence of strong efficacy for the chimeric antigen receptor T-cell (CAR-T) therapy. But the new data, which reflect product manufactured with Kite's new process, show higher rates of some side effects.

Kite Pharma Inc. presented the latest data from a trial of KTE-C19 in non-Hodgkin lymphoma as further evidence of strong efficacy for the chimeric antigen receptor T-cell (CAR-T) therapy. But the new data, which reflect product manufactured with Kite's new process, show higher rates of some side effects.

Kite teamed up with the National Cancer Institute, which did the initial development for autologous CAR-T, in 2012, and has...

More from Anticancer

More from Therapy Areas